Immunic, Inc. will host a virtual research and development day on Sept. 9, 2026, focused on relapsing multiple sclerosis, ahead of top-line data from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Chief Executive Officer Erik Lundgren, Chief Medical Officer Michael A. Panzara, Chief Scientific Officer Hella Kohlhof, and President & Chief Operating Officer Jason Tardio, alongside MS specialists Amit Bar-Or and Stephen Krieger. The company will discuss vidofludimus calcium (IMU-838), an investigational oral small molecule that combines Nurr1 activation with selective DHODH inhibition, a mechanism intended to address both neurodegenerative and inflammatory drivers of MS. Immunic also said initiation of an additional Phase 3 trial in progressive MS is expected later in 2026. The company cautioned that statements about clinical development, timing, regulatory approvals and commercial potential are forward-looking and subject to substantial risks and uncertainties.